MacroGenics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MacroGenics and other ETFs, options, and stocks.

About MGNX

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. 

CEO
Eric Risser
CEOEric Risser
Employees
293
Employees293
Headquarters
Rockville, Maryland
HeadquartersRockville, Maryland
Founded
2000
Founded2000
Employees
293
Employees293

MGNX Key Statistics

Market cap
215.14M
Market cap215.14M
Price-Earnings ratio
-3.04
Price-Earnings ratio-3.04
Dividend yield
Dividend yield
Average volume
936.30K
Average volume936.30K
High today
$3.62
High today$3.62
Low today
$3.36
Low today$3.36
Open price
$3.61
Open price$3.61
Volume
551.89K
Volume551.89K
52 Week high
$3.88
52 Week high$3.88
52 Week low
$1.10
52 Week low$1.10

Stock Snapshot

MacroGenics(MGNX) stock is priced at $3.39, giving the company a market capitalization of 215.14M. It carries a P/E multiple of -3.04.

On 2026-04-13, MacroGenics(MGNX) stock moved within a range of $3.36 to $3.62. With shares now at $3.39, the stock is trading +0.7% above its intraday low and -6.5% below the session's peak.

Trading activity shows a volume of 551.89K, compared to an average daily volume of 936.3K.

Over the past 52 weeks, MacroGenics(MGNX) stock has traded between a high of $3.88 and a low of $1.10.

Over the past 52 weeks, MacroGenics(MGNX) stock has traded between a high of $3.88 and a low of $1.10.

MGNX News

TipRanks 3d
MacroGenics upgraded to Buy at B. Riley after deal for Tubulus

B. Riley upgraded MacroGenics (MGNX) to Buy from Neutral with a $9 price target. Following the Gilead (GILD) deal for Tubulus earlier this week, the firm put to...

TipRanks 3d
MacroGenics upgraded to Buy from Neutral at B. Riley

B. Riley upgraded MacroGenics (MGNX) to Buy from Neutral with a $9 price target Published first on TheFly – the ultimate source for real-time, market-moving br...

TipRanks 5d
MacroGenics Resumes LINNET Trial After FDA Hold Lifted

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

50%

of 6 ratings
Buy
50%
Hold
50%
Sell
0%

More MGNX News

TipRanks 5d
MacroGenics says FDA removes partial clinical hold on Phase 2 LINNET study

MacroGenics (MGNX) announced that the U. S. FDA has removed the partial clinical hold on the company’s Phase 2 LINNET study of lorigerlimab, an investigational,...

Simply Wall St 5d
April 2026's Most Promising Penny Stocks

The U.S. market has experienced a notable climb, rising 1.2% in the last week and 33% over the past year, with earnings projected to grow significantly in the c...

April 2026's Most Promising Penny Stocks

People also own

Based on the portfolios of people who own MGNX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.